International Clinical Trials Day marked
20 May 2015
Melinda Paton would not be alive today without MIA. Over three years ago, Melinda was told she had only nine months to live due to her stage four melanoma diagnosis. After being transferred to MIA she was placed on an Anti-PD-1 clinical trial.
"I started the Anti-PD-1 trial in September and by December 2013; my tumour had gone from the bowel. When I saw the scan, I was in complete disbelief; I couldn’t believe that it had just disappeared,” says Melinda.
“When I first met with Dr Georgina Long, as a stage 4 patient, the tumour was causing me a lot of pain and I was very weak. The tumours were progressing very quickly and I had surgery in December to have a lymph node removed. After this is when I went onto PD-1, where I noticed a difference almost immediately.
“With PD-1, I don’t have any pain, I’m not tired, and I don’t feel sick. I work full time and it lets me live as normal life as possible. The access to these drugs has been lifesaving, without them there is no doubt I would have died a long time ago.”
Melinda is benefiting from Anti-PD1 immunotherapy treatments and she is able to live as normal life as possible. It is thanks to dedicated clinicians that have discovered these clinical trials that are saving patients lives and improving cancer care globally.
There is still more work to be done. Donate now.
Research projects led by MIA have been awarded almost $6 million in the latest NHMRC funding round which will enable vital progression of research into melanoma prevention and treatment.
The last decade has seen a surge in therapeutic options for advanced melanoma patients, thanks to research. However, not every patient responds to treatment and researchers are taking on the challenge to find out why.
Our first Global Melanoma Research Report shares selected research from around the world and here at MIA that is making a difference to the lives of melanoma patients now and in the future.
After 18 years as Director of the Sydney Melanoma Unit and then Executive Director of Melanoma Institute Australia, Professor John Thompson AO will step down from the position at the end of 2016.
Australian melanoma clinical practice guidelines have been published on a wiki platform for the first time as researchers try to keep up to date with emerging evidence.
Carole Renouf, CEO of Melanoma Institute Australia is asking young Australians who have been affected by melanoma to share their experiences with her.
Melanoma Institute Australia CEO Carole Renouf wants to make sure Aussies remember to take care of our skin as the festive season draws closer and we spend more time in the sun.
Can an individual’s risk factors for melanoma be used to tailor skin self-examinations and surveillance programs?
Prof Georgina Long has been appointed President-Elect Society for Melanoma Research (SMR).
The Australasian Melanoma Conference is bringing together some of the world's leading researchers and clinicians.
Best practice guidelines for melanoma care have gone digital with the first-ever online guidelines developed to adapt to the rapid change in clinical management.
Congratulations are in order for two of our talented researchers.
Professor Richard Scolyer will be sharing his expertise on melanoma pathology at the upcoming Australasian Melanoma Conference. Here he discusses what he'll be presenting on.
Researchers at MIA have established a High Risk Clinic to monitor people at very high risk of developing melanoma.
A generous donation has enabled a medical oncologist from Portugal to learn from the best in the world at MIA.
MIA is hosting a conference to bring together greats minds in melanoma research that will make a difference to the lives of melanoma patients
Meet Michelle, our Translational Research Officer whose role is to connect the clinics to the lab by ensuring patient blood and tissue samples are documented and carefully stored in our BioSpecimen Bank.
Dr James Wilmott says his Wildfire Award will help expand research into treatment options for people with mucosal melanoma, a rare but deadly form of skin cancer.
Following the recent hype around immunotherapies in cancer, CEO Carole Renouf shares the greatest story never told… resistance… and what MIA is doing to address it.
A/Prof Wargo discusses the research she will be presenting as a keynote speaker at the upcoming Australasian Melanoma Conference.